BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 17913245)

  • 21. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
    J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
    Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
    Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
    Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
    Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mannan-modified adenovirus as a vaccine to induce antitumor immunity.
    Ding ZY; Wu Y; Luo Y; Su JM; Li Q; Zhang XW; Liu JY; He QM; Yang L; Tian L; Zhao X; Deng HX; Wen YJ; Li J; Kang B; Wei YQ
    Gene Ther; 2007 Apr; 14(8):657-63. PubMed ID: 17287861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice.
    Zhao F; Dou J; Wang J; Chu L; Tang Q; Wang Y; Li Y; Cao M; Hu W; Hu K; Feng He X; Gu N
    Immunobiology; 2010; 215(2):89-100. PubMed ID: 19457579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
    Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
    Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
    Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
    Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2.
    Luo Y; Wen YJ; Ding ZY; Fu CH; Wu Y; Liu JY; Li Q; He QM; Zhao X; Jiang Y; Li J; Deng HX; Kang B; Mao YQ; Wei YQ
    Clin Cancer Res; 2006 Mar; 12(6):1813-9. PubMed ID: 16551866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine.
    Wang H; Wang D; Li M; Zhou C; Ma W; Su X; Liu R; Zhang S
    Cancer Lett; 2008 Sep; 268(1):129-36. PubMed ID: 18468787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
    Chakraborty M; Abrams SI; Coleman CN; Camphausen K; Schlom J; Hodge JW
    Cancer Res; 2004 Jun; 64(12):4328-37. PubMed ID: 15205348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
    Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
    Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.
    Choi BK; Kim YH; Kang WJ; Lee SK; Kim KH; Shin SM; Yokoyama WM; Kim TY; Kwon BS
    Cancer Res; 2007 Sep; 67(18):8891-9. PubMed ID: 17875731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.